drugset / Trial / NCT00478114
Efficacy and Safety of Sorafenib in Advanced Renal Cell Carcinoma (RCC)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is the early access programme (EAP) of sorafenib in the indication of advanced renal cell carcinoma (RCC). The study is to evaluate the efficacy and safety of sorafenib in patients with advanced RCC.
Timeline
- Start
- 2007-05
- Primary completion
- 2009-08
- Completion
- 2010-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sorafenib | Small molecule | 400 mg | Oral |